Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 15 Mar 2018 This trial has been completed in Czech Republic.
- 10 Jan 2018 Planned End Date changed from 15 Jan 2018 to 30 Apr 2018.
- 17 Oct 2017 Planned primary completion date changed from 15 Oct 2017 to 30 Oct 2017.